Literature DB >> 31211839

Host Immune Markers Distinguish Clostridioides difficile Infection From Asymptomatic Carriage and Non-C. difficile Diarrhea.

Ciaran P Kelly1, Xinhua Chen1, David Williams2, Hua Xu1, Christine A Cuddemi1, Kaitlyn Daugherty1, Caitlin Barrett1, Mark Miller3, Agnès Foussadier3, Aude Lantz3, Alice Banz3, Nira R Pollock4,5.   

Abstract

BACKGROUND: Recent data indicate that Clostridioides difficile toxin concentrations in stool do not differentiate between C. difficile infection (CDI) and asymptomatic carriage. Thus, we lack a method to distinguish a symptomatic patient with CDI from a colonized patient with diarrhea from another cause. To address this, we evaluated markers of innate and adaptive immunity in adult inpatients with CDI (diagnosed per US guidelines), asymptomatic carriage, or non-CDI diarrhea.
METHODS: CDI-NAAT patients had clinically significant diarrhea and positive nucleic acid amplification testing (NAAT) and received CDI treatment. Carrier-NAAT patients had positive stool NAAT but no diarrhea. NAAT-negative patients (with and without diarrhea) were also enrolled. A panel of cytokines and anti-toxin A and B immunoglobulin (Ig) were measured in serum; calprotectin and anti-toxin B Ig A/G were measured in stool. NAAT-positive stool samples were tested by an ultrasensitive toxin assay (clinical cutoff, 20 pg/mL).
RESULTS: Median values for interleukin (IL)-4, IL-6, IL-8, IL-10, IL-15, granulocyte colony-stimulating factor (GCSF), MCP-1, tumor necrosis factor α (TNF-α), and IgG anti-toxin A in blood and IgA/G anti-toxin B in stool were significantly higher in CDI patients compared with all other groups (P < .05). Concentration distributions for IL-6, GCSF, TNF-α, and IgG anti-toxin A in blood, as well as IgA and IgG anti-toxin B in stool, separated CDI patients from all other groups.
CONCLUSIONS: Specific markers of innate and adaptive immunity distinguish CDI from all other groups, suggesting potential clinical utility for identifying which NAAT- and toxin-positive patients with diarrhea truly have CDI.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 C. difficilezzm321990 ; acquired immunity; carriage; diarrhea; innate immunity

Mesh:

Substances:

Year:  2020        PMID: 31211839      PMCID: PMC8204484          DOI: 10.1093/cid/ciz330

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  27 in total

1.  Saccharomyces boulardii inhibits ERK1/2 mitogen-activated protein kinase activation both in vitro and in vivo and protects against Clostridium difficile toxin A-induced enteritis.

Authors:  Xinhua Chen; Efi G Kokkotou; Nasima Mustafa; K Ramakrishnan Bhaskar; Stavros Sougioultzis; Michael O'Brien; Charalabos Pothoulakis; Ciarán P Kelly
Journal:  J Biol Chem       Date:  2006-06-30       Impact factor: 5.157

2.  Point-Counterpoint: What Is the Optimal Approach for Detection of Clostridium difficile Infection?

Authors:  Ferric C Fang; Christopher R Polage; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2017-01-11       Impact factor: 5.948

3.  Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity.

Authors:  Hua Yu; Kevin Chen; Ying Sun; Mihaela Carter; Kevin W Garey; Tor C Savidge; Sridevi Devaraj; Mary Elizabeth Tessier; Erik C von Rosenvinge; Ciaran P Kelly; Marcela F Pasetti; Hanping Feng
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

Review 4.  Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories.

Authors:  Carey-Ann D Burnham; Karen C Carroll
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

5.  Comparison of Clostridioides difficile Stool Toxin Concentrations in Adults With Symptomatic Infection and Asymptomatic Carriage Using an Ultrasensitive Quantitative Immunoassay.

Authors:  Nira R Pollock; Alice Banz; Xinhua Chen; David Williams; Hua Xu; Christine A Cuddemi; Alice X Cui; Matthew Perrotta; Eaman Alhassan; Brigitte Riou; Aude Lantz; Mark A Miller; Ciaran P Kelly
Journal:  Clin Infect Dis       Date:  2019-01-01       Impact factor: 9.079

6.  Development and Validation of Digital Enzyme-Linked Immunosorbent Assays for Ultrasensitive Detection and Quantification of Clostridium difficile Toxins in Stool.

Authors:  Linan Song; Mingwei Zhao; David C Duffy; Joshua Hansen; Kelsey Shields; Manida Wungjiranirun; Xinhua Chen; Hua Xu; Daniel A Leffler; Susan P Sambol; Dale N Gerding; Ciarán P Kelly; Nira R Pollock
Journal:  J Clin Microbiol       Date:  2015-07-22       Impact factor: 5.948

7.  Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.

Authors:  Michelle Hughes; Taha Qazi; Adam Berg; Janice Weinberg; Xinhua Chen; Ciaran P Kelly; Francis A Farraye
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

Review 8.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

9.  Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease.

Authors:  Suchitra K Hourigan; Sankar R Chirumamilla; Tracy Ross; Jonathan E Golub; Shervin Rabizadeh; Shehzad A Saeed; Charles O Elson; Ciaran P Kelly; Karen C Carroll; Maria Oliva-Hemker; Cynthia Sears
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

10.  Clostridium difficile flagella induce a pro-inflammatory response in intestinal epithelium of mice in cooperation with toxins.

Authors:  Jameel Batah; Hussein Kobeissy; Phuong Trang Bui Pham; Cécile Denève-Larrazet; Sarah Kuehne; Anne Collignon; Claire Janoir-Jouveshomme; Jean-Christophe Marvaud; Imad Kansau
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

View more
  9 in total

1.  Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection.

Authors:  Carolyn D Alonso; Ciarán P Kelly; Kevin W Garey; Anne J Gonzales-Luna; David Williams; Kaitlyn Daugherty; Christine Cuddemi; Javier Villafuerte-Gálvez; Nicole C White; Xinhua Chen; Hua Xu; Rebecca Sprague; Caitlin Barrett; Mark Miller; Agnès Foussadier; Aude Lantz; Alice Banz; Nira R Pollock
Journal:  Clin Infect Dis       Date:  2022-07-06       Impact factor: 20.999

2.  Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum.

Authors:  Rebecca Sprague; Karolyne Warny; Nira Pollock; Kaitlyn Daugherty; Qianyun Lin; Hua Xu; Christine Cuddemi; Caitlin Barrett; Xinhua Chen; Alice Banz; Aude Lantz; Kevin W Garey; Anne J Gonzales-Luna; Carolyn D Alonso; Javier A Villafuerte Galvez; Ciarán P Kelly
Journal:  Dig Dis Sci       Date:  2020-11-08       Impact factor: 3.487

3.  Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes.

Authors:  Gregory R Madden; William A Petri; Deiziane V S Costa; Cirle A Warren; Jennie Z Ma; Costi D Sifri
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

4.  Analysis of Intestinal Mycobiota of Patients with Clostridioides difficile Infection among a Prospective Inpatient Cohort.

Authors:  Yangchun Cao; Lamei Wang; Shanlin Ke; Ciarán P Kelly; Nira R Pollock; Javier A Villafuerte Gálvez; Kaitlyn Daugherty; Hua Xu; Junhu Yao; Yulin Chen; Yang-Yu Liu; Xinhua Chen
Journal:  Microbiol Spectr       Date:  2022-07-14

5.  The value of fecal calprotectin in Clostridioides difficile infection: A systematic review.

Authors:  Bao-Jiang Wen; Li-Ger Te; Xiao-Xuan Liu; Jian-Hong Zhao
Journal:  Front Physiol       Date:  2022-08-03       Impact factor: 4.755

6.  Integrating gut microbiome and host immune markers to understand the pathogenesis of Clostridioides difficile infection.

Authors:  Shanlin Ke; Nira R Pollock; Xu-Wen Wang; Xinhua Chen; Kaitlyn Daugherty; Qianyun Lin; Hua Xu; Kevin W Garey; Anne J Gonzales-Luna; Ciarán P Kelly; Yang-Yu Liu
Journal:  Gut Microbes       Date:  2021 Jan-Dec

7.  Fecal Mycobiota Combined With Host Immune Factors Distinguish Clostridioides difficile Infection From Asymptomatic Carriage.

Authors:  Yangchun Cao; Lamei Wang; Shanlin Ke; Javier A Villafuerte Gálvez; Nira R Pollock; Caitlin Barrett; Rebecca Sprague; Kaitlyn Daugherty; Hua Xu; Qianyun Lin; Junhu Yao; Yulin Chen; Ciarán P Kelly; Yang-Yu Liu; Xinhua Chen
Journal:  Gastroenterology       Date:  2021-03-05       Impact factor: 33.883

8.  Two-step Testing for Clostridioides Difficile is Inadequate in Differentiating Infection From Colonization in Children.

Authors:  Jacob M Parnell; Irtiqa Fazili; Sarah C Bloch; D Borden Lacy; Valeria A Garcia-Lopez; Rachel Bernard; Eric P Skaar; Kathryn M Edwards; Maribeth R Nicholson
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-03-01       Impact factor: 3.288

9.  Humoral Immune Response to Clostridioides difficile Toxins A and B in Hospitalized Immunocompromised Patients With C difficile Infection.

Authors:  Carolyn D Alonso; Konstantinos Papamichael; Rebecca Sprague; Caitlin Barrett; Anne J Gonzales-Luna; Kaitlyn Daugherty; Kevin W Garey; Javier Villafuerte-Gálvez; Hua Xu; Qianyun Lin; Lamei Wang; Xinhua Chen; Nira R Pollock; Ciarán P Kelly
Journal:  Open Forum Infect Dis       Date:  2021-06-01       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.